Can-Fite BioPharma Ltd, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver, and inflammatory diseases, today announced that its previously majority-owned subsidiary OphthaliX, Inc....
READ MORE
|
How long does it take Congress to reach an agreement on drug prices? On the topic of drug misclassifications in Medicaid, about two and a half years. That’s the time that’s passed since Mylan’s famous EpiPen saga and the Justice Department settlement that followed. Finally, lawmakers have passed the Right Rebate Act, hoping to crack down on drug misclassifications that lower drugmaker rebates and cost taxpayers. And now the bill is headed to the president's desk. The legisl...
FIERCEPHARMA
READ MORE
|
Medtronic plc, the global leader in medical technology, and Mercy, the fifth largest Catholic health care system in the U.S, together will establish a new data sharing and analysis network that helps gather clinical evidence for medical device innovation and patient access....
READ MORE
|
Studying how individual cells are affected by chemical compounds, viral infections, and other agents can have profound practical consequences for the development of new drugs and novel therapies for disease. Conventionally, antivirals are studied in terms of how they influence entire cellular cultures, which can lead to researchers missing important events that happen in only some cells. To observe individual cells, lab techs have to manually load individual cells into dozens of plate wells, whi...
READ MORE
|
Novan, Inc. (NASDAQ: NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a prescription pharmaceutical business specializing in dermatology. Upon execution of the agreement, Sato will pay to Novan an initial payment of 1.25 billion JPY (approximately $11.0 million) for the exclusive rights to develop and commercialize in Japan Novan’s topical nitric oxide-releasing product candidate SB204 and ...
READ MORE
|
What’s in a winning drug name? BioMarin should know. For the second time, one of its products won our #FierceMadness drug name tournament—and we've only run two naming contests. The winner is decided by voters who chose the best names from recent approvals in round-by-round match-ups leading to a final championship. In our 2015 naming contest, BioMarin's Vimizim won. Brineura, this year’s BioMarin winner, beat AstraZeneca’s Imfinzi in the final match, thanks in la...
FIERCEPHARMA
READ MORE
|